Guided Therapeutics Inc. has announced the completion of patient enrollment for its clinical trial involving the LuViva Advanced Cervical Scan, a device designed for the rapid and painless detection of cervical cancer using patented biophotonic technology. The study, which was conducted across four clinical sites, enrolled approximately 430 patients, meeting the company's primary objective for 2025. The data analysis phase is now underway and includes an external review of biopsy samples, data entry from study case report forms, and statistical analysis as per the study protocol. The company anticipates filing the clinical report with the FDA later this year. The trial reported no adverse events linked to the use of LuViva, supporting its designation as a non-significant risk device by the FDA. Results from the statistical analyses are expected to be presented in the future.